Lanier, WL. Additional insights into pergolide-associated valvularheart disease. Mayo Clin Proc. 2003; 78(6):684–6.
Gilbert, DL, Dure, L, Sethuraman, G, Raab, D, Lane, J, Sallee, FR. Ticreduction with pergolide in a randomized controlled trial inchildren. Neurology. 2003; 60(4):606–11.
Lipinski, JF, Sallee, FR, Jackson, C, Sethuraman, G. Dopamineagonist treatment of Tourette disorder in children: Results of an open-label trial of pergolide. Mov Disord. 1997; 12(3):402–7.
Pritchett, AM, Morrison, JF, Edwards, WD, Schaff, HV, Connolly, HM, Espinosa, RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002; 77(12):1280–6.
Pergolide mesilate: strengthened warning. WHO drug information v17i1, 37. 2003.
Hendrikx, M, Van Dorpe, J, Flameng, W, Daenen, W. Aortic and mitralvalve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis. 1996; 5(2):235–7.
Redfield, MM, Nicholson, WJ, Edwards, WD, Tajik, AJ. Valve diseaseassociated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med. 1992; 117(1):50–2.
Flaherty, KR, Bates, JR. Mitral regurgitation caused by chronicergotamine use. Am Heart J.
Connolly, HM, Crary, JL, McGoon, MD, Hensrud, DD, Edwards, BS, Edwards, WD, et al.
Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337(9):581–8.
Robiolio, PA, Rigolin, VH, Wilson, JS, Harrison, JK, Sanders, LL, Bashore, TM, et al.
Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995; 92(4): 790–5.
Millan, MJ, Maiofiss, L, Cussac, D, Audinot, V, Boutin, JA, Newman-Tancredi, A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002; 303(2):791–804.
Shaunak, S, Wilkins, A, Pilling, JB, Dick, DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry. 1999; 66(1):79–81.
Jimenez-Jimenez, FJ, Lopez-Alvarez, J, Sanchez-Chapado, M, Montero, E, Miquel, J, Sierra, A, et al.
Retroperitoneal fibrosis in a patient with Parkinson’s disease treated with pergolide. Clin Neuropharmacol. 1995; 18(3):277–9.
Mondal, BK, Suri, S. Pergolide-induced retroperitoneal fibrosis. Int JClin Pract. 2000; 54(6):403.
Agarwal, P, Fahn, S, Frucht, SJ. Diagnosis and management of pergolide-induced fibrosis. Mov Disord. 2004; 19(6):699–704.
Moher, D, Cook, DJ, Eastwood, S, Olkin, I, Rennie, D, Stroup, DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999; 354(9193):1896–1900.
Van Camp, G, Flamez, A, Cosyns, B, Goldstein, J, Perdaens, C, Schoors, D. Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology. 2003; 61(6): 859–61.
Van Camp, G, Flamez, A, Cosyns, B, Weytjens, C, Muyldermans, L, Van Zandijcke, M, et al.
Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004; 363(9416):1179–83.
Horvath, J, Fross, RD, Kleiner-Fisman, G, Lerch, R, Stalder, H, Liaudat, S, et al.
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. MovDisord. 2004; 19(6):656–62.
Baseman, DG, O’Suilleabhain, PE, Reimold, SC, Laskar, SR, Baseman, JG, Dewey, RB Jr.
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology. 2004; 63(2):301–4.
Flowers, CM, Racoosin, JA, Lu, SL, Beitz, JG. The US Food and DrugAdministration’s registry of patients with pergolide-associatedvalvular heart disease. Mayo Clin Proc. 2003; 78(6):730–1.
Chaudhuri, KR, Dhawan, V, Basu, S, Jackson, G, Odin, P. Valvularheart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord. 2004; 19(12):1522–3.
Tanner, CM, Chhablani, R, Goetz, CG, Klawans, HL. Pergolidemesylate: lack of cardiac toxicity in patients with cardiac disease. Neurology. 1985; 35(6):918–21.
Varsano, S, Gershman, M, Hamaoui, E. Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema. Respiration. 2000; 67(5):580–2.
Leibowitz, M, Lieberman, A, Goldstein, M, Neophytides, A, Kupersmith, M, Gopinathan, G, et al.
Cardiac effects of pergolide. Clin Pharmacol Ther. 1981; 30(6):718–23.
Grosset, KA, Grosset, DG. Pergolide in Parkinson’s disease: time fora change?
Lancet. 2004; 363(9424):1907–8.
Valvular health disease with pergolide. Prescrire Int. 2003; 12(68):225.
Rahimtoola, SH. Drug-related valvular heart disease: here we goagain: will we do better this time?
Mayo Clin Proc. 2002; 77(12):1275–7.
Rascol, O, Pathak, A, Bagheri, H, Montastruc, JL. New concerns aboutold drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord. 2004; 19(6):611–3.
Boudoulas, H. Etiology of valvular heart disease. Expert RevCardiovasc Ther. 2003; 1(4):523–32.
Boudoulas, H, Vavuranakis, M, Wooley, CF. Valvular heart disease:the influence of changing etiology on nosology. J Heart Valve Dis. 1994; 3(5):516–26.
Balachandran, KP, Stewart, D, Berg, GA, Oldroyd, KG. Chronicpericardial constriction linked to the antiparkinsonian dopamineagonist pergolide. Postgrad Med J.
Tintner, R, Manian, P, Gauthier, P, Jankovic, J. Pleuropulmonaryfibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005; 62(8): 1290–5.
Thalamas, C, Rajman, I, Kulisevsky, J, Lledo, A, Mackie, AE, Blin, O, et al.
Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease. Clin Neuropharmacol. 2005; 28(3):120–5.
Storch, A, Trenkwalder, C, Oehlwein, C, Winkelmann, J, Polzer, U, Hundemer, HP, et al.
High-dose treatment with pergolide in Parkinson’s disease patients with motor fluctuations and dyskinesias. Parkinsonism Relat Disord. 2005.
Waller, EA, Kaplan, J, Heckman, MG. Valvular heart disease inpatients taking pergolide. Mayo Clin Proc. 2005; 80(8):1016–20.
Singh, JP, Evans, JC, Levy, D, Larson, MG, Freed, LA, Fuller, DL, et al.
Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999; 83(6):897–902.
Seghatol, FF, Rigolin, VH. Appetite suppressants and valvular heartdisease. Curr Opin Cardiol. 2002; 17(5):486–92.
Mast, ST, Jollis, JG, Ryan, T, Anstrom, KJ, Crary, JL. The progressionof fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med. 2001; 134(4):261–6.
Hensrud, DD, Connolly, HM, Grogan, M, Miller, FA, Bailey, KR, Jensen, MD. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc. 1999; 74(12):1191–7.
Donmez Colakoglu, B. Valvular heart disease in pergolide treatmentin Parkinson’s disease. Book of Abstracts. 16th International Congress on Parkinson’s Disease and Related Disorders. 2005; 251.
Agmon, Y. Frequency of restrictive valvular heart disease in patientswith Parkinson’s disease treated with pergoide, an ergot derived anti-parkinsonian drug: a case-control echocardiography study. Book of abstracts. 16th International Congress on Parkinson’s Disease and Related Disorders. 2005; 251.
Wolf, E. Valvular heart disease in Parkinson’s disease vs controls: anechocardiography study. Book of Abstracts. 16th International Congress on Parkinson’s Disease and Related Disorders. 2005; 251.